Verastem Oncology Posts 2-Year Follow-Up Data From RAMP 201
Verastem Oncology reported two-year median follow-up results from Phase 2 RAMP 201 in recurrent LGSOC, showing durable efficacy and no new safety signals, including an increase in median DoR for KRAS wild-type patients from 9.2 to 12 months.Material DetailsContext by AI AnalystThis is a late confir…